09:24:30 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.

Kalender

2022-09-21 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020
2020-09-23 14:21:59
OSLO, SEPTEMBER 23 2020 

CFO for hire AS, a company fully owned by Stig Jarle Pettersen, CFO of EXACT
Therapeutics AS, has on 21 September 2020 transferred 11,250 shares from its VPS
account to the VPS account of Theranostic Consulting SAS, a company fully owned
by Dr Jean-Claude Provost, Board member of EXACT Therapeutics AS. 
The background for this transaction is that Theranostic Consulting SAS did not
have a VPS account at the time of the listing of EXACT Therapeutics, a
requirement of the Merkur market. Consequently, the shares were held by CFO for
hire AS until a VPS account for Theranostic Consulting SAS was established. 
Following this transaction, Theranostic Consulting SAS has 11,250 shares in
EXACT Therapeutics AS and CFO for hire AS has 42,000 shares in EXACT
Therapeutics AS, of which 12,000 shares are held on behalf of Dr Jean Michel
Cossery, Board member of the company.

About EXACT EXACT-Tx is a clinical stage Anglo-Norwegian biotech company
developing a technology platform for targeted therapeutic enhancement – Acoustic
Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to
ultrasound-mediated, targeted drug enhancement – with the potential to
significantly amplify the clinical utility of a wide range of therapeutic agents
across a multitude of indications including within oncology (chemotherapy,
immunotherapy), infectious diseases, and neurological conditions. 

www.exact-tx.com
 
For more information contact: 

Dr Rafiq Hasan, CEO of EXACT-Therapeutics 
Rafiq@exact-tx-com 

Richard Hayhurst/Janet Joy 
Tel +44 7711 821527 
richard@rhapr.eu